This paper is the third comprehensive literature review on the cardiac marker NT-proBNP.
This new paper is based on 577 studies, reviews and commentaries published in the global medical literature between mid-2009 and March 2014.
It documents the length and breadth of the burgeoning evidence of NT-proBNP’s value as a screening and re exive test in life insurance underwriting.
Together with the NT-proBNP mortality study by Clark et al, this paper should put to rest any lingering questions or reservations in this regard.
Over the last decade, given the advent of sufficient technology, a few American insurers began experimenting with the concept of underwriters working from home.
In the intervening years, the prevalence of what we call "remote" or "telecommuting" underwriters has increased dramatically.
Considering that the potential for new sales in the so-called "middle market" is said to be upwards of $10 trillion, it is no surprise that this is one of the hottest topics in the life insurance industry.
After chronically under-serving this market for decades, carriers are now focusing on ways to cost-effectively write larger volumes of coverage on persons earning between, say, $50,000 to $150,000 annually.
The risk implications of failure to take medication as prescribed are not widely-appreciated by underwriters. To address this issue, Hank wrote a comprehensive paper on insurability issues related to nonadherence. This unique research paper was funded by Milliman Intelliscript.
"The World Health Organization has estimated that, by 2020, motor vehicle accidents (MVAs) will be second only to ischemic heart disease as a cause of years of life lost and third as a cause of disability after ischemic heart disease and depression."
"Although alcohol-related fatal crashes were substantially reduced between 1982 and 1995, there has been little change over the last 10 years."